11月21日，开开实业盘中下跌2.06%，截至10:09，报14.28元/股，成交1.53亿元，换手率6.56%，总市值 37.51亿元。 资金流向方面，主力资金净流出1055.20万元，特大单买入0.00元，占比0.00%，卖出648.79万元，占比 4.24%；大单买入2197.28万元，占比14.36%，卖出2603.69万元，占比17.01%。 开开实业所属申万行业为：医药生物-医药商业-医药流通。所属概念板块包括：SPD概念、民营医院、 小盘、中药、医药电商等。 截至9月30日，开开实业股东户数3.37万，较上期减少7.03%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，开开实业实现营业收入8.25亿元，同比增长10.76%；归母净利润1286.78万元，同比减少 62.81%。 分红方面，开开实业A股上市后累计派现1.91亿元。近三年，累计派现3474.90万元。 机构持仓方面，截止2025年9月30日，开开实业十大流通股东中，招商证券(香港)有限公司位居第三大 流通股东，持股113.11万股，持股数量较上期不变。BOCI SECURITIES LIMITED位居第七大流通股 东 ...

Core Viewpoint - The stock of Dongfang Ocean has shown a slight increase in price, with significant trading activity and a mixed flow of funds, indicating investor interest despite recent financial challenges [1][2]. Group 1: Stock Performance - On November 21, Dongfang Ocean's stock rose by 2.11%, reaching 2.91 CNY per share, with a trading volume of 2.23 billion CNY and a turnover rate of 5.12%, resulting in a total market capitalization of 57.01 billion CNY [1]. - Year-to-date, the stock price has increased by 0.69%, with a 6.99% rise over the last five trading days and an 8.99% increase over the last twenty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Dongfang Ocean reported a revenue of 246 million CNY, a year-on-year decrease of 0.78%, and a net profit attributable to shareholders of -105 million CNY, reflecting a 51.43% decline compared to the previous year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 83.97 million CNY since its A-share listing [3]. Group 3: Business Overview - Dongfang Ocean, established on December 19, 2001, and listed on November 28, 2006, is primarily engaged in seawater seed breeding, aquaculture, seafood processing, biotechnology, bonded warehousing logistics, and the development, production, and sales of in vitro diagnostic reagents [2]. - The company's revenue composition includes processing of raw materials (47.77%), trade (11.46%), and other segments, with a minor contribution from sea cucumbers (5.43%) and vaccinations (0.23%) [2]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.68% to 72,500, while the average number of circulating shares per person increased by 11.69% to 21,809 shares [2]. - Notably, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3].

截至9月30日，开开实业股东户数3.37万，较上期减少7.03%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，开开实业实现营业收入8.25亿元，同比增长10.76%；归母净利润1286.78万元，同比减少 62.81%。 责任编辑：小浪快报 分红方面，开开实业A股上市后累计派现1.91亿元。近三年，累计派现3474.90万元。 开开实业今年以来股价跌9.66%，近5个交易日跌2.49%，近20日涨1.63%，近60日跌1.22%。 今年以来开开实业已经1次登上龙虎榜，最近一次登上龙虎榜为1月2日，当日龙虎榜净买入-1120.05万 元；买入总计5518.17万元 ，占总成交额比8.51%；卖出总计6638.22万元 ，占总成交额比10.24%。 资料显示，上海开开实业股份有限公司位于上海市静安区昌平路678号一楼，成立日期1997年8月4日， 上市日期2001年2月28日，公司主营业务涉及以中医药流通、中医药学服务(中医问诊服务)和服装批 发、零售为主营业务。主营业务收入构成为：批发类74.48%，零售类18.18%，卫生服务类4.42%，租赁 类1.77%，其他1.14%。 机构持仓方面， ...

今年以来开开实业已经1次登上龙虎榜，最近一次登上龙虎榜为1月2日，当日龙虎榜净买入-1120.05万 元；买入总计5518.17万元 ，占总成交额比8.51%；卖出总计6638.22万元 ，占总成交额比10.24%。 资料显示，上海开开实业股份有限公司位于上海市静安区昌平路678号一楼，成立日期1997年8月4日， 上市日期2001年2月28日，公司主营业务涉及以中医药流通、中医药学服务(中医问诊服务)和服装批 发、零售为主营业务。主营业务收入构成为：批发类74.48%，零售类18.18%，卫生服务类4.42%，租赁 类1.77%，其他1.14%。 开开实业所属申万行业为：医药生物-医药商业-医药流通。所属概念板块包括：SPD概念、民营医院、 医药电商、小盘、中药等。 11月19日，开开实业盘中下跌2.01%，截至10:48，报14.11元/股，成交1.02亿元，换手率4.46%，总市值 37.06亿元。 资金流向方面，主力资金净流出433.08万元，特大单买入113.11万元，占比1.11%，卖出0.00元，占比 0.00%；大单买入1198.49万元，占比11.72%，卖出1744.68万元，占比17.0 ...

Core Viewpoint - Dahu Co., Ltd. has shown a significant increase in stock price and trading activity, indicating positive market sentiment despite a decline in revenue for the first nine months of 2025 [1][2]. Group 1: Stock Performance - As of November 19, Dahu Co., Ltd. saw a stock price increase of 2.05%, reaching 6.48 CNY per share, with a trading volume of 1.42 billion CNY and a turnover rate of 4.63%, resulting in a total market capitalization of 31.18 billion CNY [1]. - The stock has appreciated by 37.29% year-to-date, with a 6.75% increase over the last five trading days, 14.69% over the last 20 days, and 15.10% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Dahu Co., Ltd. reported a revenue of 645 million CNY, reflecting a year-on-year decrease of 15.69%. However, the net profit attributable to shareholders was -565,600 CNY, showing a significant year-on-year increase of 97.36% [2]. - The company has cumulatively distributed 44.18 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Group 3: Shareholder Information - As of November 10, the number of shareholders for Dahu Co., Ltd. stood at 42,100, with an average of 11,438 circulating shares per shareholder, indicating no change from the previous period [2]. - Notable institutional holdings include the Noan Multi-Strategy Mixed Fund, which is the third-largest shareholder with 2.57 million shares, and the Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, which increased its holdings by 405,000 shares to 2.56 million shares [3].

Core Viewpoint - Baolait's stock price has shown a mixed performance this year, with a year-to-date increase of 36.72%, but a recent decline in trading activity and a net outflow of funds indicates potential investor concerns [2][1]. Company Overview - Baolait Medical Technology Co., Ltd. is located in Zhuhai, Guangdong Province, established on June 28, 1993, and listed on July 19, 2011. The company specializes in the research, production, sales, and service of medical device products [2]. - The main revenue composition includes hemodialysis products (77.51%), monitoring equipment (21.39%), and other products (1.10%) [2]. Financial Performance - For the period from January to September 2025, Baolait reported operating revenue of 793 million yuan, a year-on-year decrease of 1.77%. The net profit attributable to shareholders was -8.34 million yuan, showing a year-on-year increase of 38.85% [2]. - Cumulative cash dividends since the A-share listing amount to 244 million yuan, with 35.16 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Baolait had 21,200 shareholders, an increase of 15.06% from the previous period. The average circulating shares per person decreased by 13.10% to 9,974 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (165531) is the ninth largest with 1.055 million shares, marking its entry as a new shareholder [3].

Core Viewpoint - Meinian Health's stock price has shown a positive trend, with a year-to-date increase of 21.04%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Meinian Health reported a revenue of 6.925 billion yuan, a year-on-year decrease of 3.01%, while the net profit attributable to shareholders reached 51.86 million yuan, reflecting a significant year-on-year increase of 110.53% [2]. - The company has cumulatively distributed 634 million yuan in dividends since its A-share listing, with 127 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 17, Meinian Health's stock price was 5.54 yuan per share, with a market capitalization of 21.685 billion yuan. The stock experienced a trading volume of 327 million yuan and a turnover rate of 1.53% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on February 19, where it recorded a net buy of -155 million yuan [1]. Shareholder Structure - As of September 30, 2025, Meinian Health had 152,000 shareholders, a decrease of 11.85% from the previous period. The average number of circulating shares per person increased by 13.44% to 25,490 shares [2]. - The top ten circulating shareholders include notable ETFs, with Huabao Zhongzheng Medical ETF holding 88.664 million shares, a decrease of 15.1218 million shares from the previous period [3].

11月17日，通化金马盘中上涨2.23%，截至11:05，报29.39元/股，成交3.93亿元，换手率1.41%，总市值 284.05亿元。 资金流向方面，主力资金净流出1759.63万元，特大单买入2862.41万元，占比7.28%，卖出4253.98万 元，占比10.82%；大单买入1.15亿元，占比29.36%，卖出1.19亿元，占比30.29%。 通化金马所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：民营医院、工业大麻、 东北振兴、肝炎治疗、中药等。 截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 ...

11月17日，安科生物盘中下跌2.03%，截至10:04，报10.61元/股，成交1.13亿元，换手率0.86%，总市值 177.45亿元。 安科生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：民营医院、基因测 序、互联医疗、医疗美容、肝炎治疗等。 截至10月31日，安科生物股东户数7.69万，较上期增加4.63%；人均流通股15886股，较上期减少 4.43%。2025年1月-9月，安科生物实现营业收入19.63亿元，同比增长2.15%；归母净利润5.51亿元，同 比减少6.48%。 分红方面，安科生物A股上市后累计派现26.62亿元。近三年，累计派现12.52亿元。 机构持仓方面，截止2025年9月30日，安科生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1952.26万股，相比上期减少126.90万股。招商国证生物医药指数A（161726）位居第五大 流通股东，持股1596.17万股，相比上期减少273.29万股。创新药（159992）位居第七大流通股东，持股 1121.77万股，相比上期增加19.13万股。南方中证1000ETF（512100）位居第九大流通 ...

Core Viewpoint - Langzi Co., Ltd. has shown significant stock performance with a year-to-date increase of 34.52%, reflecting strong market interest and financial growth [1][2]. Financial Performance - For the period from January to September 2025, Langzi Co., Ltd. achieved a revenue of 4.328 billion yuan, representing a year-on-year growth of 3.58% [2]. - The net profit attributable to shareholders reached 989 million yuan, marking a substantial year-on-year increase of 372.50% [2]. Stock Market Activity - As of November 17, the stock price of Langzi Co., Ltd. was 21.47 yuan per share, with a market capitalization of approximately 9.499 billion yuan [1]. - The stock experienced a trading volume of 1.11 billion yuan, with a turnover rate of 2.06% [1]. - Over the last five trading days, the stock price increased by 2.00%, and over the last 20 days, it rose by 23.60% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 10.93% to 51,400, while the average circulating shares per person increased by 12.27% to 4,957 shares [2][3]. - The company has distributed a total of 1.4 billion yuan in dividends since its A-share listing, with 376 million yuan distributed in the last three years [3]. Business Segmentation - The main business revenue composition includes non-surgical medical beauty (41.59%), women's dresses (11.34%), and women's tops (11.22%) among others [1].